Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is up 1.3% in afternoon trade today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $280.08. At time of writing on Wednesday, shares are swapping hands for $283.60 apiece.

As you can see on the chart below, that leaves the biotech stock down around 6% since this time last year.

As you can also see, CSL enjoyed a big rebound at the end of October, with shares up more than 22% since 31 October.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

But for the CSL share price to hit $500 it would need to gain another 79% from current levels.

Is that achievable in just three years?

According to the analysts at Macquarie, it most certainly is.

Why the CSL share price could soar from here

As a bit of background, CSL has three operating arms: CSL Behring (the company's blood plasma segment), CSL Vifor, and its Seqirus businesses.

The company acquired CSL Vifor, a global leader in iron deficiency therapies, in 2022 for US$11.7 billion.

While Vifor has been struggling to achieve growth since that acquisition, it's the Behring division that Macquarie believes could help propel the CSL share price to new heights.

As The Australian Financial Review reports, Macquarie's analysts believe the biotech giant is trading significantly below its 10-year average price-to-earnings (P/E) ratio. Macquarie expects CSL to trade back at historic P/E ratios amid annual earnings growth of some 15%.

That's based expectations that CSL Behring will make up 90% of that earnings growth over the next five years.

As for the CSL share price hitting $500 in three years, the analysts said, "We see this as both attractive and achievable."

Indeed, when CSL reported its half-year results on 13 February, CEO Paul McKenzie said:

For FY 2024, I am pleased to reaffirm our previous guidance. CSL's underlying profit, NPATA is expected to be in the range of approximately $2.9 billion to $3.0 billion at constant currency, representing growth over FY23 of approximately 13% to 17%.

Scott Olsson, a portfolio manager at Firetrail Investments' Australian high conviction fund, which owns CSL stock, is also bullish on the outlook for the CSL share price, citing a pullback in the high costs encountered during the pandemic alongside an improved outlook for the company's plasma collections.

According to Olsson (quoted by the AFR):

We think CSL presents a buying opportunity now because the market is more sceptical on management than it has been in the past, and the Vifor acquisition is turning out to not be a great buy so far, but that's a very small part of the business. I think the market is quite distracted on a few things."

What are other experts saying?

Atop Macquarie and Firetrail, a number of other investment experts are bullish on the outlook for the CSL share price.

As the Motley Fool reported yesterday, Morgans has an 'add' rating and $315.40 price target on the ASX 200 biotech stock's shares.

The analysts at UBS recently gave CSL the equivalent of a 'buy' rating, with a $330.00 price target.

Now, these are 12-month price targets, mind you, while Macquarie's $500 a share forecast for CSL is a three-year prediction.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »